Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Consolidation in Elderly Esophageal Cancer
NCT06413342Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Sintilimab Group with Observation Group (2 arms). Primary endpoint: Median Progression-Free Survival. Started Jun 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06413342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413342.